Giulia Gliozzo

Giulia Gliozzo

Auto-generated profile, based on publicly available information

Giulia Gliozzo

Dipartimento di Medicina e chirurgia traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
VDVerena Damiani
Verena Damiani
GGGianfranco Di Giuseppe
Gianfranco Di Giuseppe
GGGiulia Gliozzo
Giulia Gliozzo
GCGea Ciccarelli
Gea Ciccarelli
EPErika Pizzinato
Erika Pizzinato
TMTeresa Mezza
Teresa Mezza
Alterations in first-phase insulin secretion are pivotal in the early development of T2DM. BAG3 has been implicated in regulating insulin secretion in murine models, but its role in humans remains unexplored. This study investigates BAG3 expression in human pancreatic islets and its relationship with β-cell functionality. Pancreatic tissue samples were obtained from 12 patients with no previous T2DM diagnosis enrolled for partial pancreatectomy. Patients underwent deep metabolic evaluation, including OGTT, hyperglycemic clamp and euglycemic hyperinsulinemic clamp. Immunofluorescence and confocal microscopy were used to assess BAG3-insulin colocalization and further correlated with metabolic findings, categorizing subjects into LOW and HIGH BAG3 groups. Patients with HIGH BAG3 expression exhibited significantly impaired first-phase insulin secretion, evidenced by reduced rate sensitivity during OGTT and higher plasma glucose levels at 30 and 60 min post-glucose challenge. Islets from HIGH BAG3 patients showed increased size but no differences in insulin/glucagon ratios or insulin sensitivity, suggesting a specific disruption in the insulin secretory machinery rather than β-cell mass or insulin resistance. BAG3 appears associated to first-phase insulin secretion in humans by influencing insulin granule exocytosis. Targeting BAG3 could represent a novel therapeutic approach to prevent or delay β-cell dysfunction and the onset of T2DM.

6 June 2026 in Diabetologia
Verified
Journal Article
Closed access
EAElena Aiello
Elena Aiello
GGGiuseppina Emanuela Grieco
Giuseppina Emanuela Grieco
MBMichela Brunetti
Michela Brunetti
GGGiulia Gliozzo
Giulia Gliozzo
DFDaniela Fignani
Daniela Fignani
TMTeresa Mezza
Teresa Mezza

29 September 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
SLSara Sofia De Lucia
Sara Sofia De Lucia
GCGea Ciccarelli
Gea Ciccarelli
GGGiulia Gliozzo
Giulia Gliozzo
GGGianfranco Di Giuseppe
Gianfranco Di Giuseppe
LSLaura Soldovieri
Laura Soldovieri
TMTeresa Mezza
Teresa Mezza
Context: Fatty pancreas is associated with obesity and metabolic alterations and may coexist with pancreatic structural remodeling. However, its contribution to β-cell dysfunction remains unclear. Objective: We investigated the relationship between pancreatic fat, tissue remodeling, and β-cell function. Design: We conducted a cross-sectional study in individuals with ultrasound-detected pancreatic hyperechogenicity without prior diagnosis of diabetes. Pancreatic fat was quantified by magnetic resonance imaging (MRI)-derived proton density fat fraction, while tissue stiffness was assessed by shear wave elastography. Metabolic phenotyping was based on oral glucose tolerance test (OGTT). Participants: We recruited 29 individuals with ultrasound-detected fatty pancreas (F/M 16/13, age 54 ± 10.4 years) and assessed glucose tolerance with OGTT: 75.9% exhibited normal glucose tolerance (n = 22), while 24.1% had impaired glucose tolerance (n = 7). Results: MRI-derived pancreatic fat fraction was positively correlated with anthropometric measures (body mass index ρ = 0.43, P = .02) and β-cell function (β-cell glucose sensitivity ρ = 0.40, P = .03). Pancreatic stiffness correlated negatively with body weight (ρ = −0.38, P = .04), did not correlate with pancreatic fat fraction (ρ = −0.15, P = .44), and was correlated inversely with the potentiation factor ratio 1 (ρ = −0.44, P = .02), a measure of non–glucose-dependent amplification of insulin secretion. Conclusion: Intrapancreatic fat and pancreatic stiffness appear to reflect distinct pathophysiological processes, with potentially different relationships to systemic metabolic status and β-cell function. These findings support a more nuanced view of pancreatic structural alterations as heterogeneous markers of metabolic dysfunction.

4 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
EAElena Aiello
Elena Aiello
GGGiuseppina Emanuela Grieco
Giuseppina Emanuela Grieco
MBMichela Brunetti
Michela Brunetti
GGGiulia Gliozzo
Giulia Gliozzo
DFDaniela Fignani
Daniela Fignani
TMTeresa Mezza
Teresa Mezza
Aims/hypothesis: Type 2 diabetes mellitus (T2D) is a multifactorial disease marked by progressive beta cell dysfunction; however, no reliable, easily measurable and non-invasive circulating biomarkers are currently available to track this decline. Since microRNAs (miRNAs) tightly regulate beta cell physiology and are secreted and found in blood, we investigated whether specific circulating miRNAs may reflect in vivo beta cell function in living donors. Methods: We conducted a cross-sectional study on two independent cohorts: a discovery cohort composed by 78 individuals with different glucose tolerance [23 with normal glucose tolerance (NGT), 22 with impaired glucose tolerance (IGT), and 33 with T2D] and a validation cohort composed by 158 subjects [71 non-diabetic (ND) and 87 with T2D] who were administered an oral glucose tolerance test (OGTT) and/or a mixed meal test (MMT) with measurement of glucose, insulin and C-peptide. Plasma RNA was profiled by small RNA sequencing and differences between glucose tolerance groups were analysed using DESeq2. Linear regression analyses were used to associate miRNA abundance to clinical and metabolic measures. Droplet Digital PCR (ddPCR) was used to validate selected miRNAs. A LASSO model was used to select a set of features predictive of beta cell function. Results: We identified eleven differentially expressed miRNAs across the three glucose tolerance groups of the discovery cohort. Integrated analyses pinpointed a three-miRNAs signature (miR-34a-5p, miR-1306-5p and miR-335-5p) each significantly correlated with beta cell rate sensitivity (RS), an early indicator of insulin secretory impairment. Incorporating this panel with age and 1-hour post-load glucose into a LASSO regression model enabled accurate prediction of RS (Spearman ρ=0.43, p<0.05). Model performance was confirmed in the validation cohort of 71 ND and 87 T2D subjects (Spearman ρ=0.23, p<0.05). To streamline its clinical use, we substituted fasting glucose for 1-hour post-load glucose while retaining miRNA levels and age; this adaptation preserved predictive power (Spearman ρ=0.46, p<0.05 discovery; ρ=0.15, p=0.06 validation). Conclusion/interpretation: This three-miRNAs signature combined with simple clinical parameters constitutes a promising, non-invasive biomarker for early beta cell dysfunction and T2D progression. Research in context: What is already known about this subject?: Beta cell dysfunction is a key event in Type 2 Diabetes (T2D) pathogenesis Circulating microRNAs (miRNAs) are biomarkers linked to T2D onset and T2D-associated metabolic abnormalities What is the key question?: Can specific circulating miRNAs serve as reliable biomarkers of beta cell dysfunction across different stages of glucose tolerance and Type 2 Diabetes (T2D)? What are the new findings?: Small RNA profiling of plasma samples from deep metabolically characterized NGT, IGT, and T2D subjects revealed circulating miRNAs significantly associated with in-vivo beta cell function, reflecting key mechanisms underlying pancreatic beta cell physiology A specific set of three circulating miRNAs- miR-34a-5p, miR-1306-5p and miR-335-5p - resulted linked to beta cell dysfunction This three-miRNA signature can predict early alterations in insulin secretion, representing a promising non-invasive biomarker for the early identification of individuals at risk of developing T2D How might this impact on clinical practice in the foreseeable future?: Integrating circulating miRNA profiling with routine baseline clinical parameters could provide a simpler, non-invasive, and more accessible method to identify individuals at risk of beta cell dysfunction and T2D. Implementing miRNA-based diagnostics could facilitate personalized monitoring of disease progression. Graphical